RBC Capital Reaffirms Their Hold Rating on Pliant Therapeutics (PLRX)
RBC Capital analyst Brian Abrahams maintained a Hold rating on Pliant Therapeutics (PLRX – Research Report) yesterday and set a price target of ...
North American Morning Briefing: Trump's Tariffs -2-
2seventy bio Inc (TSVT) is expected to report $-0.20 for 4Q. 908 Devices Inc (MASS) is expected to report $-0.39 for 4Q. ATN International Inc (ATNI) is expected to report $-0.24 for 4Q. Aclaris ...
Needham downgrades Pliant Therapeutics (PLRX) to a Hold
Pliant Therapeutics (PLRX – Research Report) received a Hold rating and price target from Needham analyst Joseph Stringer today. The ...